This study aims to test a new treatment called PDR-001 for Parkinson's Disease (PD). PD is a brain disorder caused by harmful proteins called α-synuclein, which damage brain cells. Current treatments have limitations, so this study explores if PDR-001 can remove these proteins safely and effectively. PDR-001 is a special protein that targets and reduces α-synuclein, possibly slowing or stopping PD.

Participants will have PDR-001 delivered directly to their brain using a method called bilateral stereotaxic injection. This involves small surgery to place the treatment in the right spot.

To join, you must be aged 40-65, have had PD for 5 years or less, and not have other brain disorders or surgeries. You cannot join if you have certain health issues or infections, like hepatitis or HIV.

• The study involves surgery, requiring careful consideration of risks.
• Participants will help test a potential new way to treat PD, aiming to slow or stop the disease.
• Eligibility requires specific health criteria and no major brain surgery history.